Epigallocatechin Gallate Inhibits Hepatitis B Virus Infection in Human Liver Chimeric Mice

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2018 Sep 8

PMID 30189898

Citations 15

Authors

Yu-Heng Lai

Cheng-Pu Sun

Hsiu-Chen Huang

Jui-Chieh Chen

Hui-Kang Liu

Cheng Huang

Affiliations

Soon will be listed here.

Abstract

Background: Persistent hepatitis B virus (HBV) infection causes liver cirrhosis and hepatocellular carcinoma and constitutes a major worldwide health problem. Currently, anti-HBV drugs are limited to peginterferon and nucleos(t)ide analogs, which are costly and have considerable side effects; the development of novel, effective anti-HBV agents is crucial.

Methods: Catechins are a major group of compounds found in green tea extract and epigallocatechin gallate (EGCG) has been shown to have antiviral properties, including inhibition of cellular entry by HBV. FRG (Fah/ Rag2/ IL-2Rγ) mice were used in this study to generate chimeras carrying human primary hepatocytes, to facilitate investigation of the inhibitory effect of EGCG on HBV infection.

Results: Here, we show the inhibitory effect of EGCG on HBV infection and replication in HuS-E/2 cells. The inhibitory effect of EGCG on HBV infection in vivo was confirmed by monitoring HBV DNA and HBsAg in serum and immunostaining the liver tissues of the human liver chimeric mice.

Conclusions: The effects of EGCG suggest a robust strategy for the treatment of HBV infection and EGCG may have therapeutic potential for the treatment of HBV-associated liver diseases.

Citing Articles

Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.

Baei B, Askari P, Askari F, Kiani S, Mohebbi A PLoS One. 2025; 20(1):e0316765.

PMID: 39804828 PMC: 11730388. DOI: 10.1371/journal.pone.0316765.

Antiviral Effects and Mechanisms of Active Ingredients in Tea.

Zhang X, Yu H, Sun P, Huang M, Li B Molecules. 2024; 29(21).

PMID: 39519859 PMC: 11547931. DOI: 10.3390/molecules29215218.

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action.

Naderi M, Salavatiha Z, Gogoi U, Mohebbi A Front Cell Infect Microbiol. 2024; 14:1356003.

PMID: 38487354 PMC: 10937540. DOI: 10.3389/fcimb.2024.1356003.

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma.

Li D, Cao D, Cui Y, Sun Y, Jiang J, Cao X Front Pharmacol. 2023; 14:1201085.

PMID: 37292151 PMC: 10244546. DOI: 10.3389/fphar.2023.1201085.

Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation.

Wang Y, Jin S, Li D, Jiang X, Afrasiyab , Khalid A Am J Cancer Res. 2023; 13(4):1407-1424.

PMID: 37168333 PMC: 10164806.

References

Song J, Lee K, Seong B . Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005; 68(2):66-74. DOI: 10.1016/j.antiviral.2005.06.010. View

Mak J . Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol. 2012; 39(3):265-73. DOI: 10.1111/j.1440-1681.2012.05673.x. View

Zuo G, Li Z, Chen L, Xu X . Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res. 2007; 76(1):86-92. DOI: 10.1016/j.antiviral.2007.06.001. View

Bissig K, Le T, Woods N, Verma I . Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci U S A. 2007; 104(51):20507-11. PMC: 2154461. DOI: 10.1073/pnas.0710528105. View

Shirakami Y, Sakai H, Kochi T, Seishima M, Shimizu M . Catechins and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016; 929:67-90. DOI: 10.1007/978-3-319-41342-6_4. View

Chen Y, Tsai H, Peng C . EGCG debilitates the persistence of EBV latency by reducing the DNA binding potency of nuclear antigen 1. Biochem Biophys Res Commun. 2012; 417(3):1093-9. DOI: 10.1016/j.bbrc.2011.12.104. View

Watashi K, Urban S, Li W, Wakita T . NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014; 15(2):2892-905. PMC: 3958888. DOI: 10.3390/ijms15022892. View

Isaacs C, Xu W, Merz G, Hillier S, Rohan L, Wen G . Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus. Antimicrob Agents Chemother. 2011; 55(12):5646-53. PMC: 3232753. DOI: 10.1128/AAC.05531-11. View

Isaacs C, Wen G, Xu W, Jia J, Rohan L, Corbo C . Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother. 2008; 52(3):962-70. PMC: 2258520. DOI: 10.1128/AAC.00825-07. View

10.

Huang H, Chen C, Chang W, Tao M, Huang C . Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012; 86(17):9443-53. PMC: 3416113. DOI: 10.1128/JVI.00873-12. View

11.

Ide K, Kawasaki Y, Kawakami K, Yamada H . Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review. Curr Med Chem. 2016; 23(42):4773-4783. DOI: 10.2174/0929867324666161123091010. View

12.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

13.

Verrier E, Schuster C, Baumert T . Advancing hepatitis B virus entry inhibitors. J Hepatol. 2016; 66(4):677-679. PMC: 5362280. DOI: 10.1016/j.jhep.2016.11.028. View

14.

Mercer D, Schiller D, Elliott J, Douglas D, Hao C, Rinfret A . Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7(8):927-33. DOI: 10.1038/90968. View

15.

Cooper A, Paran N, Shaul Y . The earliest steps in hepatitis B virus infection. Biochim Biophys Acta. 2003; 1614(1):89-96. DOI: 10.1016/s0005-2736(03)00166-4. View

16.

Grompe M . Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat. 1993; 2(2):85-93. DOI: 10.1002/humu.1380020205. View

17.

Huang H, Tao M, Hung T, Chen J, Lin Z, Huang C . (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res. 2014; 111:100-11. DOI: 10.1016/j.antiviral.2014.09.009. View

18.

Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E . Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007; 25(8):903-10. PMC: 3404624. DOI: 10.1038/nbt1326. View

19.

Liu S, Li H, Chen L, Yang L, Li L, Tao Y . (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells. Carcinogenesis. 2012; 34(3):627-37. DOI: 10.1093/carcin/bgs364. View

20.

Chen W, Oon C . Human hepatitis B virus mutants: significance of molecular changes. FEBS Lett. 1999; 453(3):237-42. DOI: 10.1016/s0014-5793(99)00704-8. View